Response to the letter by Udo Bonnet by Venkatesan, Thangam et al.
Neurogastroenterology & Motility. 2020;32:e13715.	 wileyonlinelibrary.com/journal/nmo	 	 | 	1 of 1
https://doi.org/10.1111/nmo.13715
© 2019 John Wiley & Sons Ltd 
 
DOI: 10.1111/nmo.13715  
L E T T E R  T O  T H E  E D I T O R
Response to the letter by Udo Bonnet
We appreciate your interest in our article1 and agree that the two 
cases cited meet an acceptable diagnostic threshold for cannabinoid 
hyperemesis syndrome (CHS). These cases had long‐term follow‐up 
and improvement after cannabis abstinence, implying that heavy 
cannabis use contributed to their recurrent vomiting. However, we 
would like to restate our position that CHS is a subset of cyclic vomit‐
ing syndrome (CVS), triggered by chronic, heavy cannabis exposure.2 
If cannabis were the sole cause of hyperemesis, we would expect 
more CHS‐afflicted individuals, especially given its widespread use. 
However, only 7 cases met Rome IV criteria for CHS in a popula‐
tion‐based US study.3 In another recent investigation, 41% of 140 
CVS patients reported current cannabis use 4; 50/57 (88%) cannabis 
users abstained for >1 month but only one individual experienced 
resolution of hyperemesis and was the only patient who met Rome 
criteria for CHS. Of note, this patient remains symptom‐free despite 
resuming cannabis with higher cannabidiol (CBD).4
These rare cases of purported CHS raise important questions. 
Why do most chronic cannabis users not develop hyperemesis? Are 
there genetic variants that predispose them to vomit? The endocan‐
nabinoid system plays an important role in regulating nausea and 
vomiting. Cannabis acts primarily on cannabinoid receptor type 1 
(CB1R). We reported both increased and decreased risk of CVS in 
individuals with different CBR1 gene polymorphisms.5 It is plausible 
that genetically susceptible individuals develop symptoms when ex‐
posed to triggers such as cannabis (particularly high potency prod‐
ucts) and stress in complex gene‐environment interactions.
Cyclic vomiting syndrome and CHS are phenotypically similar 
except for chronic cannabis use. The hot‐water bathing behavior is 
not pathognomonic of CHS and is seen in ~40% of CVS patients who 
do not use cannabis. Future studies to understand the effects of 
chronic cannabis in vomiting disorders are warranted, given increas‐
ing cannabis legalization.
We agree that gastric emptying can be delayed by cannabis 
and is accelerated in nearly 60% of CVS patients.6,7 However, ab‐
normalities are not universal in CVS or CHS, and hyperemesis does 
not clearly improve with therapies which slow or stimulate gastric 
emptying. Emptying impairments may be markers of autonomic dys‐
function and probably do not cause symptoms in either condition.
In summary, we reiterate that CHS is likely a subset of CVS and 
chronic cannabis use can trigger symptoms in genetically predis‐
posed individuals. This is supported by the literature and our collec‐
tive experience caring for these patients.
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